James Matchison, MD
Interventional Cardiology · Torrance, CANPI 1629275631
Payments from drug & device makers
Across 510 payments — averaging $65.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$16K
- Abiomed$7K
- Boston Scientific$2K
- Shockwave Medical, Inc$2K
- Philips North America LLC$919
- Medtronic$860
- plus $4K from 28 others
What the payments were for
- Consulting fees$12,50037%
- Speaking & faculty fees$2,7508%
- Travel & lodging$2,6368%
- Food & beverage$15,44546%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 110 | $16,448 |
| Abiomed | 45 | $7,268 |
| Boston Scientific | 91 | $2,413 |
| Shockwave Medical, Inc | 34 | $1,646 |
| Philips North America LLC | 9 | $919 |
| Medtronic(2 entities) | 30 | $860 |
| Novartis | 40 | $497 |
| Abbott | 13 | $473 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $420 |
| E.r. Squibb & Sons, L.L.C. | 29 | $415 |
| Johnson & Johnson | 22 | $377 |
| Pfizer | 20 | $372 |
| Livanova USA, Inc. | 2 | $192 |
| Astellas Pharma US Inc | 6 | $113 |
| Amgen | 5 | $113 |
| Cardiva Medical, Inc. | 4 | $109 |
| Terumo Medical Corporation | 1 | $99 |
| Teleflex LLC | 4 | $85 |
| Kestra Medical Technology Services, Inc. | 3 | $64 |
| Novo Nordisk | 3 | $57 |
| Scpharmaceuticals Inc. | 2 | $50 |
| AstraZeneca | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $31 |
| Bridgebio Pharma, Inc. | 1 | $30 |
| GSK | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Acist Medical Systems, Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$6,680
- Edwards SAPIEN 3 Transcatheter Heart Valve$6,499
- SAPIEN 3 Ultra RESILIA$1,019
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$950
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$506
- AVVIGO Guidance System$379
- (6575) Coronary Undivided$257
- (5044) MCOT$200
- CROSSBOSS$169
- Xience Sierra Coronary Stent$151
- General - Balloon Catheters$138
- Vascular Lithotripsy$136
- (6574) Coronary Other$118
- IGT D Coronary$114
- TandemLife$108
- (BQ9) Coronary IVUS$104
How this compares
$33,340 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 473 | $553,653 |
| EntrestoSacubitril/Valsartan | 95 | $127,553 |
| Repatha SureclickEvolocumab | 109 | $90,318 |
| XareltoRivaroxaban | 59 | $69,309 |
| FarxigaDapagliflozin Propanediol | 47 | $47,822 |
| JardianceEmpagliflozin | 26 | $35,779 |
| Praluent PenAlirocumab | 22 | $16,057 |
| BrilintaTicagrelor | 18 | $14,819 |
| VascepaIcosapent Ethyl | 15 | $9,738 |
| Nebivolol Hcl | 88 | $6,456 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $5,394 |
| Metoprolol Succinate | 280 | $4,828 |
| Ranolazine ErRanolazine | 18 | $4,420 |
| Atorvastatin Calcium | 424 | $4,328 |
| ClopidogrelClopidogrel Bisulfate | 270 | $3,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $372 | $553,653473 claims |
| NovartisEntresto | $497 | $127,55395 claims |
| Johnson & JohnsonXarelto | $377 | $69,30959 claims |
| AstraZenecaFarxiga, Brilinta | $50 | $62,64165 claims |
| Boehringer IngelheimJardiance | $16 | $35,77926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Torrance
- Ray WymanTorrance$289K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.